Search

Regeneron Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

800.7 -0.61

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

789.59

Max

806.15

Galvenie mērījumi

By Trading Economics

Ienākumi

570M

1.3B

Pārdošana

685M

4.3B

P/E

Sektora vidējais

19.42

57.002

EPS

12.53

Dividenžu ienesīgums

0.46

Peļņas marža

30.226

Darbinieki

15,410

EBITDA

576M

1.5B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+2.85% upside

Dividendes

By Acuity

Dividenžu ienesīgums

Sektora vidējais

0.46%

2.22%

Nākamie ieņēmumi

2026. g. 27. okt.

Nākamais dividenžu datums

2026. g. 31. aug.

Nākamais Ex dividenžu datums

2026. g. 18. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

13B

83B

Iepriekšējā atvēršanas cena

801.31

Iepriekšējā slēgšanas cena

800.7

Ziņu noskaņojums

By Acuity

10%

90%

14 / 340 Rangs Healthcare

Regeneron Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 13. aug. 19:16 UTC

News
Social Media

Regeneron Pharmaceuticals is trading higher as social media highlights REGN17235's potential in ongoing clinical trials, supporting strong performance since Wednesday's close.

2026. g. 12. aug. 23:01 UTC

News

Regeneron Pharmaceuticals faces a securities fraud lawsuit over misleading statements regarding its Phase III Fianlimab-Libtayo Study, contributing to lower after-market trading.

2026. g. 11. aug. 23:01 UTC

Regeneron Pharmaceuticals shares are modestly higher in after-market hours. No specific company news was identified to explain this movement.

2026. g. 10. aug. 20:02 UTC

Regeneron Pharmaceuticals Inc shares are higher, supported by broader market strength and reduced expectations for Federal Reserve interest rate hikes following Friday's jobs report.

2026. g. 7. aug. 22:16 UTC

News

Regeneron Pharmaceuticals shares are lower in after-market hours following a class action lawsuit alleging securities fraud and unlawful business practices.

2026. g. 6. aug. 19:26 UTC

News
Social Media

Regeneron Pharmaceuticals faces a potential class action lawsuit over alleged securities fraud, contributing to a decline in shares despite receiving Health Canada approval for Libtayo.

2026. g. 5. aug. 20:06 UTC

Regeneron Pharmaceuticals is trading higher, reflecting gains since Tuesday, amid a decline in crude oil prices that eases inflationary pressures.

2026. g. 4. aug. 23:46 UTC

Regeneron Pharmaceuticals is roughly flat in after-market trading, remaining well above its 20-day moving average and near the upper end of its one-month range.

2026. g. 3. aug. 19:46 UTC

News

Regeneron Pharmaceuticals faces class action lawsuits over alleged securities fraud related to its Phase III Fianlimab-Libtayo Study, contributing to lower share prices.

2026. g. 1. aug. 00:01 UTC

News

Regeneron Pharmaceuticals shares are lower in after-market hours following a class action lawsuit alleging securities fraud and concerns over a failed clinical trial.

2026. g. 31. jūl. 23:06 UTC

News

Regeneron Pharmaceuticals shares declined in after-market hours following a class action lawsuit alleging securities fraud related to its Phase III study modifications.

2026. g. 30. jūl. 19:49 UTC

Regeneron Pharmaceuticals is trading higher, significantly above its 20-day moving average and near the upper end of its one-month trading range.

2026. g. 29. jūl. 23:16 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, maintaining strength above the 20-day moving average despite broader market caution over rising interest rates.

2026. g. 28. jūl. 23:06 UTC

Regeneron Pharmaceuticals Inc is higher in after-hours trading, continuing its positive momentum and remaining above its 20-day moving average. No specific news was identified.

2026. g. 27. jūl. 23:51 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, maintaining momentum with strong cumulative returns and three consecutive higher daily closes.

2026. g. 25. jūl. 00:02 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, reaching the upper end of their one-month trading range. No specific news was identified.

2026. g. 24. jūl. 20:13 UTC

Regeneron Pharmaceuticals Inc shares are higher in after-market trading, remaining near the upper end of their one-month range. No specific news was identified.

2026. g. 23. jūl. 09:56 UTC

Regeneron Pharmaceuticals Inc shares are modestly higher in pre-market trading. No specific company news was identified to explain the price movement.

2026. g. 22. jūl. 23:46 UTC

Regeneron Pharmaceuticals shares are higher in after-hours trading, peaking post-market despite cautious sentiment from rising crude oil prices and geopolitical tensions.

2026. g. 21. jūl. 23:51 UTC

News

Regeneron Pharmaceuticals faces a class action lawsuit for securities fraud over misleading claims about Fianlimab-Libtayo trial results. Shares are lower in after-hours trading.

2026. g. 17. jūl. 19:26 UTC

Social Media
News

Regeneron Pharmaceuticals faces a class action lawsuit from Levi & Korsinsky, LLP, contributing to ongoing declines in the stock amid market volatility.

2026. g. 16. jūl. 20:03 UTC

Regeneron Pharmaceuticals is trading higher, supported by gains in the Biotechnology sub-sector amid a strong broader market performance today.

2026. g. 15. jūl. 19:16 UTC

Regeneron Pharmaceuticals Inc shares are higher Wednesday, recovering from an earlier dip and remaining above the 20-day moving average. No specific news was identified.

2026. g. 13. jūl. 19:26 UTC

Regeneron Pharmaceuticals shares are lower today amid broader market declines driven by rising oil prices and geopolitical tensions. No specific company news was identified.

2026. g. 11. jūl. 00:01 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, reflecting a notable gain near the upper end of its one-month trading range.

2026. g. 10. jūl. 19:26 UTC

Correlated Moves

Regeneron Pharmaceuticals Inc shares declined amid broader biotechnology sector pressures and geopolitical tensions, despite earlier reaching a session high before pulling back.

2026. g. 9. jūl. 23:51 UTC

Regeneron Pharmaceuticals Inc shares are lower in after-market hours following a weak trading session, despite a report showing a decrease in initial jobless claims.

2026. g. 8. jūl. 19:53 UTC

News

Regeneron Pharmaceuticals shares are lower, pressured by declines in the Biotechnology sector and a reduced price target of $730 from Morgan Stanley.

2026. g. 7. jūl. 23:06 UTC

Regeneron Pharmaceuticals Inc shares are higher in after-market trading, supported by stable performance and positioning above the 20-day moving average.

2026. g. 6. jūl. 23:01 UTC

Regeneron Pharmaceuticals Inc shares are lower in after-market hours, with no specific news identified to explain the decline amid mixed market sentiment.

Salīdzinājums

Cenas izmaiņa

Regeneron Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

2.85% augšup

Prognoze 12 mēnešiem

Vidējais 828.95 USD  2.85%

Augstākais 1,030 USD

Zemākais 641 USD

Pamatojoties uz 21 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Regeneron Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

21 ratings

14

Pirkt

7

Turēt

0

Pārdot

Noskaņojums

By Acuity

14 / 340 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
help-icon Live chat